Healthcare provider profile · identity verified

Chin Yi, MD

Family Practice · BELLEVILLE, MI · NPI 1649259532

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	594	138
Amlodipine Besylate	Amlodipine Besylate	439	102
Losartan Potassium	Losartan Potassium	284	59
Omeprazole	Omeprazole	272	67
Metformin Hcl	Metformin Hcl	211	53
Lisinopril	Lisinopril	207	50
Gabapentin	Gabapentin	185	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	173	27
Metoprolol Succinate	Metoprolol Succinate	135	35
Levothyroxine Sodium	Levothyroxine Sodium	123	27
Tramadol Hcl	Tramadol Hcl	123	24
Glipizide Er	Glipizide	121	30
Rosuvastatin Calcium	Rosuvastatin Calcium	118	34
Tamsulosin Hcl	Tamsulosin Hcl	108	25
Trazodone Hcl	Trazodone Hcl	104	23
Albuterol Sulfate Hfa	Albuterol Sulfate	98	28
Furosemide	Furosemide	96	22
Escitalopram Oxalate	Escitalopram Oxalate	92	21
Metoprolol Tartrate	Metoprolol Tartrate	81	21
Sertraline Hcl	Sertraline Hcl	79	15
Meloxicam	Meloxicam	73	20
Duloxetine Hcl	Duloxetine Hcl	71	12
Hydrochlorothiazide	Hydrochlorothiazide	71	22
Clopidogrel	Clopidogrel Bisulfate	69	17
Eliquis	Apixaban	68	16
Ozempic	Semaglutide	68	11
Carvedilol	Carvedilol	64	18
Pantoprazole Sodium	Pantoprazole Sodium	64	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	62	13
Diclofenac Sodium	Diclofenac Sodium	55	12
Nifedipine Er	Nifedipine	53	suppressed
Atenolol	Atenolol	52	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	11
Ibuprofen	Ibuprofen	51	16
Novolog Flexpen	Insulin Aspart	46	suppressed
Jardiance	Empagliflozin	45	15
Ondansetron Odt	Ondansetron	44	suppressed
Spironolactone	Spironolactone	44	14
Simvastatin	Simvastatin	43	13
Alendronate Sodium	Alendronate Sodium	41	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	41	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	41	suppressed
Montelukast Sodium	Montelukast Sodium	40	12
Pioglitazone Hcl	Pioglitazone Hcl	40	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	39	24
Chlorthalidone	Chlorthalidone	38	suppressed
Famotidine	Famotidine	38	12
Ipratropium Bromide	Ipratropium Bromide	37	16
Allopurinol	Allopurinol	36	11
Fluticasone Propionate	Fluticasone Propionate	36	16
Farxiga	Dapagliflozin Propanediol	33	suppressed
Celecoxib	Celecoxib	32	suppressed
Clonidine Hcl	Clonidine Hcl	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Primidone	Primidone	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	28	suppressed
Prednisone	Prednisone	27	17
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	27	suppressed
Lorazepam	Lorazepam	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	25	suppressed
Methylprednisolone	Methylprednisolone	25	20
Mirtazapine	Mirtazapine	25	suppressed
Pregabalin	Pregabalin	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	24	suppressed
Lidocaine	Lidocaine	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Alprazolam	Alprazolam	22	suppressed
Ezetimibe	Ezetimibe	22	suppressed
Hydrocortisone	Hydrocortisone	22	19
Donepezil Hcl	Donepezil Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Azithromycin	Azithromycin	20	17
Buspirone Hcl	Buspirone Hcl	20	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	12
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Cephalexin	Cephalexin	19	12
Levetiracetam	Levetiracetam	19	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	18	suppressed
Colchicine	Colchicine	18	suppressed
Finasteride	Finasteride	18	suppressed
Terbinafine Hcl	Terbinafine Hcl	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Glipizide	Glipizide	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	14
Januvia	Sitagliptin Phosphate	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Valsartan	Valsartan	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Lacosamide	Lacosamide	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Temazepam	Temazepam	13	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Erythromycin	Erythromycin Base	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error